Roberto Hegg

19.7k citations
89 papers · 8.4k · 4 hit papers · h-index 25

Impact in

  • Oncology top 0.2%
    • HER2/EGFR in Cancer Research
    • Cancer Immunotherapy and Biomarkers
    • Cancer Treatment and Pharmacology
    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics

Papers in

Roberto Hegg

81 papers receiving 8.3k citations

Roberto Hegg's Hit Papers

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial 2020 · 739 citations
7390+5+10Years since publication10002.0k3.0k

Peers

Roberto Hegg
Comparison fields: 5 of 107
  • Oncology 5.4k
  • Cancer Research 1.8k
  • Pulmonary and Respiratory Medicine 1.8k
  • Immunology 1.1k
  • Radiology, Nuclear Medicine and Imaging 1.1k
Replace Binghe Xu with:
Binghe Xu China
Peter Schmid United Kingdom
Alex Bajamonde United States
Emiliano Calvo Spain
Sara A. Hurvitz United States
Erika Hamilton United States
Eva Ciruelos Spain
Graham Ross United Kingdom
Wells A. Messersmith United States
Virginia Paton United States
Roberto Hegg relative to Binghe Xu China Binghe Xu's profile →
Citations per field
00.5×1.5×2.2×
Binghe Xu · 1×
Citations per year

Countries citing papers authored by Roberto Hegg

Since Specialization
Citations

This map shows the geographic impact of Roberto Hegg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Hegg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Hegg more than expected).

Fields of papers citing papers by Roberto Hegg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Hegg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Hegg. The network helps show where Roberto Hegg may publish in the future.

Co-authors

The 25 scholars most cited alongside Roberto Hegg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Roberto Hegg Line = papers co-authored together Roberto Hegg links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 89 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Hit paper breakdown →
20183084
2
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Hit paper breakdown →
20111789
3
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
Hit paper breakdown →
2013793
4
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Hit paper breakdown →
2020739
5 2012261
6 2019163
7 2018143
8 2016140
9 2014108
10 202081
11 202174
12 201267
13 201465
14 201763
15 200262
16 201659
17 201958
18 201655
19 200855
20 201255

About Roberto Hegg

Roberto Hegg is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Public Health, Environmental and Occupational Health, having authored 89 papers that have together received 8.4k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (30 papers), HER2/EGFR in Cancer Research (30 papers), Cancer Treatment and Pharmacology (19 papers), Breast Cancer Treatment Studies (16 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Cancer, Lipids, and Metabolism (4 papers), Ovarian cancer diagnosis and treatment (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). The work is most often cited by research in Oncology (5.4k citations), Cancer Research (1.8k citations), Pulmonary and Respiratory Medicine (1.8k citations), Immunology (1.1k citations) and Radiology, Nuclear Medicine and Imaging (1.1k citations). Roberto Hegg has collaborated with scholars based in Brazil, United States and Spain. Frequent co-authors include Seock‐Ah Im, Hiroji Iwata, Carlos H. Barrios, Javier Cortés, Luciana Molinero, Jane Yuet Ching Hui, Peter Schmid, Hope S. Rugo, Amreen Husain and Volkmar Henschel. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Breast Cancer Research and Treatment and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact